

Samarbejdsaftale

1. Parter

Mellem undertegnede

Roche Pharmaceuticals a/s

(herefter kaldet "Virksomheden")

og

medundertegnede

Brystkræftforeningen

(herefter kaldet "Organisationen")

(herefter i fællesskab benævnt "Parterne")

er der indgået følgende aftale om samarbejde.

2. Samarbejdsaftalens formål

Formålet med samarbejdsaftalen er, at yde økonomisk støtte til produktion af 2 nye afsnit af Brystkræftforeningens podcastserie "Os med Brystkræft".

3. Samarbejdsprojektets navn

Samarbejdsprojektets navn er "2 podcasts"

4. Parternes rolle i samarbejdet

Virksomheden forpligter sig med nærværende samarbejdsaftale til at yde økonomisk støtte til organisationens produktion af 2 nye afsnit i serien "Os med Brystkræft". Støtten gives under forudsætning af, at de to podcasts ikke indeholder information om konkrete medicinske behandlinger.

Organisationen forpligter sig til at sikre, at anvende midlerne til at producere 2 podcasts samt at omtale i de to pågældende podcasts, at virksomheden er sponsor.



5. Tidsramme

Samarbejdet, hvis nærmere formål og omfang er beskrevet i pkt. 2 og 4, skal afvikles fra underskrivelse af samarbejdsaftalen og til 31. september 2026.

Parternes rettigheder og forpligtelser i henhold til nærværende samarbejdsaftale løber fra underskriftsdato og indtil samarbejdsaftalens forpligtelser er opfyldt, medmindre andet udtrykkeligt er aftalt.

6. Pris for ydelsen

30.000 kr., inkl. moms

7. Ikke-finansiell ydelse

Ej relevant.

8. Offentliggørelse

Nærværende samarbejdsaftale er offentligt tilgængelig på Virksomhedens hjemmeside www.roche.dk frem til 31. september 2028.

Jf. Etisk Nævn for Lægemiddelvirksomheders vejledning til "Etiske regler for lægemiddelindustriens samarbejde med patientforeninger mv." skal det understreges, at patientforeninger på sin hjemmeside skal offentliggøre alle økonomiske fordele, herunder økonomiske sponsorater (pengebeløb) og naturalier, som foreningen har modtaget fra lægemiddelvirksomheder, jf. reklamebekendtgørelsens § 21. Offentliggørelsen skal ske på en sådan måde, at størrelsen af økonomiske fordele fra hver enkelt virksomhed fremgår af hjemmesiden. Oplysningerne skal gøres tilgængelige på hjemmesiden senest én måned efter, at patientforeningen har modtaget den økonomiske fordel. Oplysningerne skal være tilgængelige på hjemmesiden i mindst to år.

.

9. Anvendelse af Organisationens navn

Organisationen accepterer, at Virksomheden anvender Organisationens navn i forbindelse med samarbejdet på Virksomhedens hjemmeside www.roche.dk.

10. Uafhængighed og habilitet



Parterne erklærer ved sin underskrift, at det står Organisationen frit at samarbejde med flere lægemiddelvirksomheder, ligesom Virksomheden har mulighed for at samarbejde med en eller flere organisationer. Parterne erklærer samtidig, at der ikke i samarbejdet stilles krav om eneret i forhold til konkrete produkt- eller terapiområder.

Virksomheden erklærer ved sin underskrift af nærværende samarbejdsaftale ikke at stille betingelser for organisationens faglige og interessepolitiske standpunkter.

Virksomheden erklærer ved sin underskrift ikke at have et tillidshverv i Organisationen, der har betydning for nærværende samarbejdsaftale.

11. Misligholdelse

Såfremt en af Parterne misligholder sine forpligtelser i henhold til nærværende samarbejdsaftale, kan den ikke misligholdende part ophæve samarbejdsaftalen med øjeblikkelig virkning. Den ikke misligholdende part er i øvrigt berettiget til at bringe andre efter dansk ret til rådighed stående misligholdelsesbeføjelser til anvendelse, herunder retten til at kræve erstatning, uanset om aftalen ophæves.

12. Lovvalg

Nærværende samarbejdsaftale er i enhver henseende underlagt dansk ret.

13. Konfliktløsning

Såfremt tvister ikke kan bilægges igennem mægling, skal disse indbringes for Sø- og Handelsretten i København.



14. Underskrift

København, 11.01.2026

DocuSigned by:

Anja Skjoldborg Hansen

Formand, Brystkræftforeningen

København, 19.12.2025

Signed by:

Poul Riese

Patient Partnership Lead,

Roche Pharmaceuticals a/s

19.12.2025

Signed by:

Pia Møllgaard Mikkelsen,

Business Lead

Roche Pharmaceuticals a/s



Brystkræftforeningen
Landlyst Vænge 46
2635 Ishøj
ATT: Anja Skjoldborg Hansen

Donation - udbetalingsblanket til patientforening

DocuSigned by:

90DB13A8013C4A8...

Erhvervskonto – informationer

Registrerings nr.	9570
Konto nr.	4610568696
Tekst til indbetalingen	Roche_podcast Max. 16 tegn
CVR-nr.	21 43 88 71
Tilhørende	Brystkræftforeningen
Adresse	Landlyst Vænge 46
Postnr. og by	2635 Ishøj

Donation til Patientforening DKK 30.000 (udfyldes af Roche a/s)

Totalt DKK 30.000 (udfyldes af Roche a/s)

Bemærk venligst at:

- Støtte til Patientforening kan kun udbetales til en erhvervskonto
- Al støtte til Patientforening bliver offentliggjort på www.roche.dk efter gældende regler
- Blanketten bedes returneret hurtigst muligt. Forventet ekspeditionstid er ca. 15 arbejdsdage efter modtagelse

Udfyldes af Roche Pharmaceuticals A/S

Tekst Sponsorships	Konto nr. 5501005000	WBS P.C1.PGO00.003.001
Intern Roche ansvarlig: Poul Riese		

Certificate Of Completion

Envelope Id: 5ED66514-9021-4D9A-B57E-79E0505FE6C0

Status: Completed

Subject: Brystkræftforeningen - Donation 2x podcast

Source Envelope:

Document Pages: 5

Signatures: 4

Envelope Originator:

Certificate Pages: 4

Initials: 1

pega.romedocusign

AutoNav: Enabled

Grenzacherstrasse 124

Envelopeld Stamping: Enabled

Basel, BASEL-STADT 4070

Time Zone: (UTC+01:00) Amsterdam, Berlin, Bern, Rome, Stockholm, Vienna

pega.romedocusign@roche.com

IP Address: 34.248.19.191

Record Tracking

Status: Original

Holder: pega.romedocusign

Location: DocuSign

12/19/2025 1:59:41 PM

pega.romedocusign@roche.com

Signer Events

Jacob Møller Nielsen

jacob.moller_nielsen@roche.com

Nordic_408

Security Level: Email, Account Authentication
(None)

Signature



Signature Adoption: Pre-selected Style

Using IP Address:

2001:2012:1806:2d00:4571:1e19:238a:6aa3

Timestamp

Sent: 12/19/2025 2:09:33 PM

Viewed: 12/19/2025 2:21:55 PM

Signed: 12/19/2025 2:22:06 PM

Electronic Record and Signature Disclosure:

Accepted: 5/14/2025 9:15:38 AM

ID: e95dd923-e5ba-4e01-b76b-c36758e743aa

Company Name: F.Hoffmann-La Roche Ltd - Pega_408

Poul Riese

poul.riese@roche.com

Security Level: Email, Account Authentication
(None)

Signed by:



Signature Adoption: Pre-selected Style

Using IP Address: 188.182.231.167

Sent: 12/19/2025 2:22:07 PM

Viewed: 12/19/2025 3:46:03 PM

Signed: 12/19/2025 3:46:28 PM

Electronic Record and Signature Disclosure:

Accepted: 12/19/2025 3:46:03 PM

ID: 989cca37-8bba-4db2-995a-fdc6a74ad430

Company Name: F.Hoffmann-La Roche Ltd - Pega_408

Pia Mikkelsen

pia.mollgaard@roche.com

Security Level: Email, Account Authentication
(None)

Signed by:



Signature Adoption: Drawn on Device

Using IP Address: 90.185.45.172

Signed using mobile

Sent: 12/19/2025 3:46:30 PM

Viewed: 12/19/2025 4:41:14 PM


Signed: 12/19/2025 4:42:07 PM

Electronic Record and Signature Disclosure:

Accepted: 12/19/2025 4:41:14 PM

ID: 2faff943-1cfd-43da-829f-d79a3047b4df

Company Name: F.Hoffmann-La Roche Ltd - Pega_408

Signer Events	Signature	Timestamp
Anja Skjoldborg Hansen ansk@brystkraeft.dk President of the board Security Level: Email, Account Authentication (None)	DocuSigned by:  90DB13A8013C4A8... Signature Adoption: Drawn on Device Using IP Address: 2a00:4020:5303:8900:aca1:27f2:720b:84ab	Sent: 12/19/2025 4:42:09 PM Resent: 1/9/2026 9:53:21 AM Viewed: 1/9/2026 2:11:33 PM Signed: 1/11/2026 6:19:26 PM

Electronic Record and Signature Disclosure:
Accepted: 11/19/2025 1:37:53 PM
ID: b0555c9c-0820-408e-87ff-13296236d9fa
Company Name: F.Hoffmann-La Roche Ltd - Pega_408

In Person Signer Events	Signature	Timestamp
Mirela Hansen mirela.hansen@roche.com Business Partner Roche Pharmaceuticals A/S Security Level: Email, Account Authentication (None), Login with SSO	VIEWED Using IP Address: 196.3.50.248	Sent: 12/19/2025 1:59:45 PM Viewed: 12/19/2025 2:00:11 PM Completed: 12/19/2025 2:09:32 PM

Electronic Record and Signature Disclosure:
Accepted: 10/20/2025 11:30:39 AM
ID: c1ea1031-c678-4c85-bb8e-8d870eb9a4e4
Company Name: F.Hoffmann-La Roche Ltd - Pega_408

Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	12/19/2025 1:59:45 PM
Envelope Updated	Security Checked	12/19/2025 2:09:32 PM
Envelope Updated	Security Checked	12/19/2025 2:09:32 PM
Envelope Updated	Security Checked	12/19/2025 2:09:32 PM
Envelope Updated	Security Checked	12/19/2025 2:09:32 PM
Envelope Updated	Security Checked	12/19/2025 2:09:32 PM
Envelope Updated	Security Checked	12/19/2025 2:09:32 PM
Envelope Updated	Security Checked	1/9/2026 9:53:22 AM
Certified Delivered	Security Checked	1/9/2026 2:11:33 PM
Signing Complete	Security Checked	1/11/2026 6:19:26 PM
Completed	Security Checked	1/11/2026 6:19:26 PM

Payment Events	Status	Timestamps
Electronic Record and Signature Disclosure		

Guidelines for the use of the DocuSign electronic signing system within F. Hoffmann-La Roche and companies of the Roche Group

LEGAL DISCLOSURE

By placing my electronic signature on this document, I expressly consent to use and rely on Electronic and Digital Signatures and I understand my signature will have the same binding effect as if I was providing a handwritten signature.

I also confirm the email address that I am using as a valid one to be notified and identified electronically, for example through the DocuSign System, and/or to identify me as the signer of the document. I should inform Roche in the case that the email address changes.

CONSUMER DISCLOSURE

From time to time, F. Hoffmann-La Roche and companies of the Roche Group (hereinafter referred to as we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign, Inc. (DocuSign) electronic signing system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to these terms and conditions, please confirm your consent by clicking the 'I agree' button at the bottom of this document.

Consequences of changing your mind

To indicate to us that you are changing your mind, you must withdraw your consent using the DocuSign 'Withdraw Consent' form on the signing page of a DocuSign envelope instead of signing it. This will indicate to us that you have withdrawn your consent to receive required notices and disclosures electronically from us and you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact us

You may contact us to let us know of your changes as to how we may contact you electronically, to request certain information from us and to withdraw your prior consent to receive notices and disclosures electronically. To do so contact the sender of the envelope.

To advise us of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to the sender of the envelope and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address. In addition, you must notify DocuSign, Inc. to arrange for your new email address to be reflected in your DocuSign account by following the process for changing email in the DocuSign system.

To withdraw your consent

To inform us that you no longer want to receive future notices and disclosures in electronic format you may decline to sign a document from within your DocuSign session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent.

Acknowledging your access and consent to receive materials electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please verify that you were able to read this electronic disclosure and that you also were able to print on paper or electronically save this page for your future reference and access or that you were able to email this disclosure and consent to an address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format on the terms and conditions described above, please let us know by clicking the 'I agree' button below.

By checking the 'I agree' box, I confirm that:

- I can access and read this Electronic CONSENT TO ELECTRONIC RECEIPT OF ELECTRONIC CONSUMER DISCLOSURES document; and
- I can print on paper the disclosure or save or send the disclosure to a place where I can print it, for future reference and access; and
- Until or unless I notify the account owner as described above, I consent to receive from exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to me by the account owner during the course of my relationship with you.
- I acknowledge the information included in the† [DocuSign Privacy Policy](#)